These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33247879)

  • 21. Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects.
    Ahmed RH; Huri HZ; Al-Hamodi Z; Salem SD; Muniandy S
    PLoS One; 2015; 10(10):e0140618. PubMed ID: 26474470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
    Solis-Herrera C; Triplitt C; Garduno-Garcia Jde J; Adams J; DeFronzo RA; Cersosimo E
    Diabetes Care; 2013 Sep; 36(9):2756-62. PubMed ID: 23579178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
    Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
    Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
    Ahn CH; Oh TJ; Kwak SH; Cho YM
    Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease.
    Idorn T; Knop FK; Jørgensen M; Holst JJ; Hornum M; Feldt-Rasmussen B
    Nephrol Dial Transplant; 2014 Jan; 29(1):119-27. PubMed ID: 24078334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: Results of a two-step cluster analysis.
    Amato MC; Pizzolanti G; Torregrossa V; Pantò F; Giordano C
    J Diabetes Investig; 2016 Mar; 7(2):219-25. PubMed ID: 27042274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Diagnosis of Post Pancreatitis Diabetes Mellitus Based on Pancreatic and Gut Hormone Characteristics.
    Lv Y; Lu X; Liu G; Qi L; Zhong Z; Wang X; Zhang W; Shi R; Goodarzi MO; Pandol SJ; Li L
    J Clin Endocrinol Metab; 2024 Jul; 109(8):2003-2011. PubMed ID: 38344778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.
    Gjesing AP; Ekstrøm CT; Eiberg H; Urhammer SA; Holst JJ; Pedersen O; Hansen T
    Diabetologia; 2012 May; 55(5):1338-45. PubMed ID: 22349073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes.
    Lee S; Yabe D; Nohtomi K; Takada M; Morita R; Seino Y; Hirano T
    Endocr J; 2010; 57(2):119-26. PubMed ID: 19881250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
    Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes.
    Oh TJ; Kim MY; Shin JY; Lee JC; Kim S; Park KS; Cho YM
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):221-7. PubMed ID: 23405851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLP-1 and GIP Levels in Patients With Hyperthyroidism: The Effect of Antithyroid Treatment.
    Cira DK; Sari R; Ozdem S; Yilmaz N; Bozkurt S
    Ann Pharmacother; 2017 Aug; 51(8):663-668. PubMed ID: 28452237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients.
    Alsalim W; Persson M; Ahrén B
    Diabetes Obes Metab; 2018 Jul; 20(7):1652-1658. PubMed ID: 29498469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
    Ma J; Pilichiewicz AN; Feinle-Bisset C; Wishart JM; Jones KL; Horowitz M; Rayner CK
    Diabet Med; 2012 May; 29(5):604-8. PubMed ID: 22004512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The antidiabetic action of camel milk in experimental type 2 diabetes mellitus: an overview on the changes in incretin hormones, insulin resistance, and inflammatory cytokines.
    Korish AA
    Horm Metab Res; 2014 Jun; 46(6):404-11. PubMed ID: 24627103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma glucagon responses in tropical fibrocalculous pancreatic diabetes.
    Mohan V; Snehalatha C; Ramachandran A; Chari S; Madanagopalan N; Viswanathan M
    Diabetes Res Clin Pract; 1990 Apr; 9(1):97-101. PubMed ID: 2190785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
    Meece J
    Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.